Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world
CONCLUSIONS: This analysis provides insights on PML in patients receiving natalizumab that extend current knowledge, particularly regarding PML in patients receiving natalizumab EID, which can be built upon in the future.PMID:37272350 | DOI:10.1080/14740338.2023.2221027 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - June 5, 2023 Category: Drugs & Pharmacology Authors: Liesel Dsilva Kerry McCarthy Jennifer Lyons Bernadette Cabigas Nolan Campbell George Kong Bryan Adams Robert Kuhelj Priya Singhal Karen Smirnakis Source Type: research
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
(Source: Journal of Neurology)
Source: Journal of Neurology - June 5, 2023 Category: Neurology Source Type: research
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
This cohort study investigates differences in the effectiveness and treatment persistence between dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis who switched from natalizumab. (Source: JAMA Neurology)
Source: JAMA Neurology - June 5, 2023 Category: Neurology Source Type: research
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).PMID:37265062 | DOI:10.57264/cer-2023-0016 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - June 2, 2023 Category: General Medicine Authors: Imtiaz A Samjoo Christopher Drudge Sarah Walsh Santosh Tiwari R óisín Brennan Ibolya Boer Dieter A H äring Luisa Klotz Nicholas Adlard Judit Banhazi Source Type: research
EE258 National Trends in Costs and Site of Service of Infused Disease Modifying Therapies for Multiple Sclerosis
Identify and compare national trends in ocrelizumab and natalizumab costs and site-of-service distribution over time. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: E. Pineda, A. Patel, C. Ng, N.G. Bonine Source Type: research
CO63 Comparative Clinical Effectiveness of Monoclonal Antibodies for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis
To evaluate the relative clinical effectiveness of five monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, rituximab, ublituximab) as first-line disease-modifying therapies (DMT) for relapsing forms of multiple sclerosis (MS); and to compare these treatments to placebo and oral DMTs (dimethyl fumarate, fingolimod, ozanimod, ponesimod, and teriflunomide). (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: D. Nikitin, G. Lin, A. McKenna, S. Herron-Smith, J. Campbell, F.O. Agboola Source Type: research
CO39 Real-World Assessment of Efficacy and Safety of Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Systematic Review and Meta-Analysis
The efficacy and safety of natalizumab versus fingolimod for relapsing-remitting multiple sclerosis (RRMS) had conflicting results, according to data from various medical centers across the globe. Therefore, we performed a systematic review and meta-analysis of data from real-world evidence (RWE) studies to evaluate the efficacy and safety Parameters of Natalizumab Versus Fingolimod. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: Z. Almalki Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
